Commentary|Events|November 4, 2026

Q&A: What AI Reveals That Scientists Could Not See Before

Fact checked by: Ron Panarotti

Matt Truppo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.

Artificial intelligence (AI) is no longer a peripheral tool in biopharma but rather is rapidly becoming embedded in nearly every stage of the drug development continuum, from early target identification through clinical trial design, manufacturing, and postmarket expansion. But with that integration comes a set of questions that are more complex than any algorithm alone can answer, such as: What does responsible deployment look like? Who is accountable when a model is wrong? And does AI actually move the needle on clinical and manufacturing success?

Related to this article